News

Galvus (vildagliptin) is a DPP-4 inhibitor that blocks the breakdown of incretin hormones in the body that stimulate the pancreas to produce insulin. The approval is backed by

Bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody, acts by targeting PS and thereby enabling the immune system to recognise and fight the tumor. The randomised Phase II lung cancer

According to Acetylon, Sidera proved to be a suitable choice to meet its growing data needs owing to Sidera’s reliable and secure communications network and Internet Access Service.

According to the company, Solo helps in the management of its global depot network including receipt of clinical supplies and kits, dispatches, returns, warehouse movements and QA releases.

According to Pharmabiz, the studies involved the application of Malvern’s light scattering technologies in evaluating the formulation stability of Albucult and Recombumin. The teams applied the resolving capabilities

The center will support the development and commercialization of cell therapies and advanced therapeutics, as well as the technologies for manufacturing, quality control, safety and efficiency. The Technology

The agreement provides OvaGene with worldwide rights to develop and commercialize proprietary microRNA-based assays that predict drug response for currently used cancer treating drugs. The proprietary assays were

The new division, ArjoHuntleigh Home Care, is believed to provide a broad range of product solutions that aid in patient handling systems, hygiene systems, therapeutic surfaces, medical beds,

The Company has also appointed Rajeev Venkayya as its leader of the Division effective 15 January 2012. Dr Venkayya currently serves as Director of Vaccine Delivery in the